GS1 India to Host GS1 General Assembly 2025 in Mumbai: ‘Building Bridges for a Better Tomorrow'
MUMBAI , India , May 19, 2025 /PRNewswire/ — GS1 India is proud to host the GS1 General Assembly 2025 in Mumbai from 20th to 22nd May 2025 . With the theme 'Building Bridges for a Better Tomorrow,' this prestigious annual global event brings together leaders and change makers to shape the future of global supply chains.
GS1 India will be hosting the GS1 General Assembly in Mumbai from 20th to 22nd May 2025. The event will have 250+ guests representing the GS1 Management Board comprising some of the global leading companies, and Chairmen and CEOs representing 118 Member Organizations worldwide. Together, these global leaders will explore how standards and emerging technologies are accelerating digital transformation and enabling smarter, more resilient supply chains—with a central highlight being the official approval of GS1 Vision 2030, the organisation's bold new strategic direction.
'With the approval of GS1 Vision 2030 here in India , we mark a milestone moment for our global community. This new strategy sets a bold course for the future—one where data can be trusted, shared, and acted upon in real time. In a world shaped by digital acceleration and AI, our role is to enable companies of all sizes to seamlessly reach markets, enhance supply chain efficiency and resilience, meet sustainability and regulatory demands, and empower consumers and patients with information they can trust,' said Renaud de Barbuat, President and CEO, GS1.
S. Swaminathan, CEO, GS1 India said, 'We are honoured to host the GS1 General Assembly 2025. As supply chains around the world evolve to become more digital, transparent, and resilient, this year's them reflects our collective commitment to collaboration and transformation. Through global standards, we are not just enabling smarter supply chains; we are laying the foundation for trustworthy ecosystems powered by trusted data that benefit consumers, businesses, and governments alike.'
The event will have voices from Indian industry sectors such as retail, healthcare, technology, supply chain management, and e-commerce. These leaders will explore how global standards and emerging technologies are accelerating digital transformation and creating smarter, more resilient supply chains.
Key discussion topics will include: The launch of Vision 2030 and its impact on the industry
Ambition 2027 and the global transition to next generation barcodes
The transformative impact of emerging technologies like AI and Block chain
About GS1
GS1 is a neutral, not-for-profit standards organisation that is best known for the barcode, named by the BBC as one of 'the 50 things that made the world economy.' GS1 standards improve the efficiency, safety and visibility of supply chains across physical and digital channels in 25 sectors. GS1 standards enable organisations to identify, capture and share information seamlessly. Our scale and reach – local Member Organisations in 118 countries, more than 2 million user companies and 10 billion transactions every day –ensure that GS1 standards create a common language that supports systems and processes across the globe. Find out more at www.gs1.org.
About GS1 India
GS1 India is a member organisation affiliated to GS1 Global. It has been setup by the Ministry of Commerce, Govt. of India along with trade bodies like CII, FICCI, IMC, ASSOCHAM, APEDA, FIEO and organisations such as Spices Board, Indian Institute of Packaging and BIS. Find out more at www.gs1india.org.
The GS1 General Assembly is an annual meeting which brings entire GS1 global community together and where organisation's key decisions and global disruptions are discussed.
View original content:https://www.prnewswire.com/in/news-releases/gs1-india-to-host-gs1-general-assembly-2025-in-mumbai-building-bridges-for-a-better-tomorrow-302458751.html
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Global Anticancer Drugs Market Booms with 11.3% CAGR, Driven by Targeted Therapy & Biomarkers
Anticancer Drugs Market is Segmented by Type (Cancer Immunotherapy, Targeted Therapy, Chemotherapy), by Application (Lung Cancer, Breast Cancer, Prostate Cancer, Blood-related Cancer). BANGALORE, India, June 5, 2025 /PRNewswire/ -- The global market for Anticancer Drugs was valued at USD 206090 Million in the year 2024 and is projected to reach a revised size of USD 430540 Million by 2031, growing at a CAGR of 11.3% during the forecast period. Claim Your Free Report: Major Factors Driving the Growth of Anticancer Drugs Market: The anticancer drugs market is experiencing robust growth fueled by rising cancer incidence, expanding treatment options, and technological advances. With increasing adoption of personalized medicine, immunotherapy, and biosimilars, the landscape is evolving rapidly. Pharmaceutical companies are heavily investing in R&D to develop drugs targeting various cancer types, leading to a strong pipeline. Regulatory agencies are offering expedited approvals for breakthrough therapies, encouraging innovation. The market encompasses chemotherapy, targeted therapy, hormone therapy, and biologics, catering to both early and advanced-stage cancers. As cancer becomes a global health priority, the demand for accessible, effective, and cost-efficient treatment solutions is expected to grow steadily, sustaining long-term market expansion. Unlock Insights: View Full Report Now! TRENDS INFLUENCING THE GROWTH OF THE ANTICANCER DRUGS MARKET: Cancer immunotherapy is significantly propelling the growth of the anticancer drugs market due to its ability to harness the body's immune system to combat malignant cells more effectively than traditional methods. Unlike chemotherapy, which often damages healthy cells, immunotherapy offers targeted action with fewer side effects, increasing patient preference and clinician recommendation. The emergence of immune checkpoint inhibitors, CAR T-cell therapies, and monoclonal antibodies has broadened treatment options across multiple cancer types. Its success in treating cancers that were previously resistant to standard therapies has generated strong clinical interest. Additionally, rising investments, expanding FDA approvals, and ongoing research collaborations between biotech firms and pharmaceutical companies are further accelerating the market demand for immunotherapy-based anticancer drugs. Targeted therapy is a crucial driver in the anticancer drugs market as it allows for the development of treatments designed to interfere with specific molecular targets associated with cancer progression. This precision-based approach minimizes damage to healthy tissues and improves the effectiveness of cancer treatment. Innovations in genomics and molecular diagnostics have enabled oncologists to identify mutations and biomarkers, leading to tailored therapies for individuals. Drugs targeting proteins like HER2, EGFR, and BRAF are now standard in treating cancers like breast, lung, and melanoma. With fewer side effects and improved patient outcomes, targeted therapies are preferred over conventional cytotoxic drugs. As personalized medicine gains ground globally, targeted therapy continues to fuel steady market expansion. Lung cancer remains a dominant force in driving the anticancer drugs market due to its high global incidence and mortality rate. The complex nature of lung cancer requires a broad arsenal of treatment options, including chemotherapy, targeted therapies, and immunotherapies. With advancements in early detection and biomarker testing, patients are now eligible for precision treatments that significantly improve survival rates. Governments and healthcare agencies are increasing screening programs, particularly in high-risk populations like smokers and the elderly, driving diagnosis rates and treatment uptake. The introduction of novel drugs for advanced stages of lung cancer and increased awareness has led to growing demand, significantly contributing to market revenue. The steady increase in global cancer cases is a primary factor propelling the anticancer drugs market. Factors such as aging populations, lifestyle changes, exposure to carcinogens, and rising obesity rates are contributing to this surge. According to WHO, cancer is now one of the leading causes of death globally, placing immense pressure on healthcare systems to deliver effective treatments. This rising demand compels pharmaceutical companies to accelerate drug development and approval pipelines. Public and private funding for cancer research is also increasing to support this urgency. As a result, the anticancer drugs market is expanding to cater to diverse cancer types and stages, creating a consistent need for innovative and accessible therapies. Government initiatives and healthcare policies play a vital role in boosting the anticancer drugs market. Many countries are expanding public healthcare coverage for cancer treatment, especially in developed regions like North America and Europe. Subsidized treatment programs and insurance reimbursements have made costly anticancer therapies more accessible to a broader patient base. Special provisions for rare cancers and orphan drug designations further incentivize pharmaceutical firms to innovate. Public institutions like the National Cancer Institute (NCI) and Cancer Research UK are increasing investments in clinical trials and drug discovery. Such funding and supportive policies reduce the financial burden on patients and encourage consistent demand for effective cancer medications. Biomarker research is revolutionizing how anticancer drugs are developed, prescribed, and monitored. Biomarkers help predict disease progression, treatment response, and potential side effects, allowing clinicians to personalize therapies for better outcomes. Companion diagnostics, often co-developed with anticancer drugs, guide targeted treatment decisions, improving precision and efficacy. The integration of biomarkers in clinical trials accelerates drug approvals by identifying suitable patient cohorts. This has led to faster commercialization of breakthrough therapies. Biomarker-driven treatments also reduce trial-and-error prescribing, improving healthcare efficiency. As the field of precision oncology expands, biomarker research is becoming indispensable, thereby acting as a powerful growth catalyst for the anticancer drugs market. Emerging markets across Asia, Latin America, and Africa are witnessing improved healthcare infrastructure, which supports wider access to cancer diagnosis and treatment. Governments are investing in public hospitals, telemedicine services, and awareness campaigns to facilitate early detection and treatment. Pharmaceutical companies are also forming partnerships in these regions to launch affordable versions of branded therapies. Access to generics and biosimilars further supports affordability. Mobile health technologies and e-pharmacies are helping bridge urban-rural gaps in drug delivery. With growing income levels and rising cancer burden in these regions, the demand for anticancer drugs is expanding. This regional growth trend adds significant momentum to the global market. Claim Yours Now! ANTICANCER DRUGS MARKET SHARE Global key players of Anticancer Drugs include Merck & Co, Bristol-Myers Squibb, Roche, Novartis, Johnson & Johnson, etc. The top five players hold a share over 55%. North America is the largest market, and has a share of about 55%, followed by Asia-Pacific and Europe with 21% and 19%, separately. Regionally, North America leads the anticancer drugs market due to its advanced healthcare infrastructure, high cancer prevalence, and strong research funding. The U.S. accounts for a significant share, with widespread access to innovative therapies and insurance coverage. In terms of product type, Targeted Therapy is the largest segment, occupied for a share of 58%. In terms of application, Blood-related Cancer has a share of about 23 percent. Key Companies: Novartis Pfizer Inc Amgen Inc Astrazeneca plc Merck AbbVie Johnson & Johnson Gilead Sciences Roche Bristol–Myers Squibb Takeda Merck KGaA Seagen Eli Lilly Ono Pharmaceutical GSK Exelixis Inc Regeneron Innovent Hengrui Medicine Purchase Regional Report: SUBSCRIPTION We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans. DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS! - Anthracycline Anticancer Drugs Market - The global market for Platinum-based Anticancer Drugs was estimated to be worth USD 1541.9 Million in 2023 and is forecast to a readjusted size of USD 1788.9 Million by 2030 with a CAGR of 2.1% during the forecast period 2024-2030. - Oncology Generic Injectable Drugs Market - Ovarian Cancer Treatment Drugs Market - Alkylating Agent Antineoplastic Drugs Market - The global Oncology Drugs Market revenue was USD 197440 Million in 2022 and is forecast to a readjusted size of USD 395270 Million by 2029 with a CAGR of 10.3% during the review period (2023-2029). - The global market for Oncology Treatment Drug was estimated to be worth USD 197440 Million in 2023 and is forecast to a readjusted size of USD 342140 Million by 2030 with a CAGR of 8.0% during the forecast period 2024-2030. - Esophageal Cancer Drugs Market - Mylotarg Market - Pharmaceutical Grade Anhydrous Piperazine Market - Platinum-based Anticancer APIs Market DISCOVER OUR VISION: VISIT ABOUT US! Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs. Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs. To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources. GET A FREE QUOTE Valuates Reportssales@ U.S. Toll-Free Call 1-(315)-215-3225WhatsApp: +91-9945648335Website: Logo: View original content to download multimedia: SOURCE Valuates Reports Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities
BEIJING, June 4, 2025 /PRNewswire/ -- Tsingke Biotech recently participated in TIDES USA 2025, the leading international event for oligonucleotide and peptide therapeutics, held in San Diego from May 19 to 22. As a repeat exhibitor, Tsingke highlighted its integrated "The Great Gene Factory" model, offering precision synthesis solutions from early discovery to large-scale manufacturing. During the exhibition, Tsingke showcased its core offerings including: End-to-End synthesis tools, such as the Syn-HCY Series (12P/192P/768B), delivering high-throughput oligo production for CRISPR, IVD, and research needs GMP production system, featuring the Syn-HL12 synthesizer capable of 200 nmol to 12 mmol scale, equipped with real-time monitoring for UV, pH, and conductivity Application coverage across ASO/siRNA therapeutics, gene editing, mRNA vaccine templates, and diagnostic probes Over 300 chemical modifications and a robust raw material supply chain supporting batch-to-batch consistency Visitors were particularly impressed by Tsingke's automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company's ability to integrate reagents, instruments, and services into a unified platform drew significant attention from pharmaceutical and biotech partners. Tsingke Biotech remains committed to empowering life sciences and therapeutic innovation by building a world-class platform for nucleic acid synthesis. For inquiries or collaboration, please contact us at market@ Visit: View original content to download multimedia: SOURCE Tsingke Biotech Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil
Next-generation technologies will help increase the agility and efficiency of genetic sequencing to tackle several diseases SAO PAULO, June 5, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has just expanded its partnership with the Diagnostic Support Unit (UNADIG), a non-profit laboratory of the Oswaldo Cruz Foundation (FIOCRUZ), one of Brazil's leading scientific institutions, to support public health in the country. MGI's first scientific collaboration with UNADIG was established during the COVID-19 pandemic. With the MGISP-960 extractor equipment from MGI, UNADIG was able to process more than 3 million samples from across the country during this period. With the end of the pandemic, UNADIG expanded its portfolio and included different methodological platforms in its laboratory facilities (chemiluminescence, Elisa, photometry, immunoturbidimetry, and indirect potentiometry), as well as genetic sequencing. The new agreement between UNADIG and MGI will enable maintain the molecular tests (RT-PCR) but advances in DNA-based testing. UNADIG has two large high-processing laboratories. The the Clinical Diagnostic Laboratory (DCLIN) has a daily processing capacity of around 29,000 samples, and the Molecular Diagnostic Laboratory (DIMOL) can process between 9,000 and 15,000 RT-PCR samples. In 2025, with the sequencing support of MGI, a process in molecular genetics will begin with the capacity to process over 2,000 samples weekly for the diagnosis of infectious, genetic, and main types of cancer (breast, ovarian, colorectal and prostate), in addition of individual gene sequencing for sporadic or hereditary cancers. "The goal of this collaboration is to help transform healthcare delivery, with a focus on efficiency and accessibility, as it will contribute to expanding access for the Brazilian population to high-complexity laboratory tests with greater speed and reduced costs. This will accelerate the diagnosis and treatment of oncological and epidemiological diseases, strengthening the country's response to outbreaks and epidemics", Carlos Carpio, Senior Commercial Director of MGI Latin America and General Manager for Brazil, explains. To expand its operational and analytical capacity for sample and test processing, UNADIG has acquired state-of-the-art equipment from MGI, including 14 units MGISP-960 nucleic acid extractor; 1 unit MGISP-100 automated genomic library preparation system; 2 units DNBSEQ-G400 and 1 unit DNBSEQ-T7 sequencers; and 1 unit ZTRON platform for genomic data storage and analysis. These technologies also ensure greater speed and accuracy in processing, while enhancing sample handling safety and reducing the risk of contamination. "Precision medicine brings significant benefits to patients and to the public health system, enabling early diagnoses, more effective treatments and the optimization of clinical protocols. This results in cost savings, waste reduction and greater effectiveness of tests and therapies. MGI's equipment, which allows automated processes, helps us achieve these goals", Erika Martins de Carvalho, General Coordinator of UNADIG-RJ of the Vice Presidency of Health Production and Innovation at Fiocruz, says. Increasing the presence in Brazil With the goal of making genetic sequencing more accessible, efficient and scalable through comprehensive solutions, MGI has been expanding its operations in Brazil. In 2024, the company inaugurated a Customer Experience Center in São Paulo, created to offer clinical laboratories and healthcare institutions a dedicated space for hands-on demonstrations. The center aims to enhance technical training and familiarity with MGI's technologies. Highly qualified professionals lead certified training sessions, presentations, evaluations and provide local support for new applications. Also in 2024, MGI established partnerships with Dasa, Grupo Sabin and Oncoclínicas&Co to expand the use of genetic sequencing in Brazil through the adoption of advanced technologies for genetic testing aimed at diagnosing cancers, rare diseases and other conditions, strengthening personalized medicine in the country. About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit , Linkedin, X, and Youtube. View original content to download multimedia: SOURCE MGI TECH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
